• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Amplifications of proto-oncogenes in ovarian carcinoma.

作者信息

Bian M, Fan Q, Huang S, Ma J, Lang J

机构信息

Department of Obstetrics and Gynecology, China-Japan Friendship PUMC Hospital, Beijing.

出版信息

Chin Med J (Engl). 1995 Nov;108(11):844-8.

PMID:8585978
Abstract

Thirty-two cases of ovarian carcinoma, two of normal ovaries, four of benign epithelial ovarian tumor, and three of borderline epithelial ovarian tumor were studied using Southern blot hybridization of DNA. In 15 of the 32 cases of ovarian carcinoma, peripheral lymphocytes were also studied. The amplification rate of C-myc, C-N-ras, C-Ki-ras and C-erbB-2 in ovarian carcinoma were 50%, 44%, 31% and 25% respectively. The amplification of C-Ki-ras and C-N-ras took place chiefly in cases of early stage and those of good differentiation. The amplification of C-N-ras was also found in cases of advanced stage. The amplifications of C-myc and C-erbB-2 were chiefly found in cases above stage III and those of poor differentiation. A total of 83% of the patients who died were found to have amplifications of more than 2 proto-oncogenes, with which the amplification of C-erbB-2 was involved.

摘要

相似文献

1
Amplifications of proto-oncogenes in ovarian carcinoma.
Chin Med J (Engl). 1995 Nov;108(11):844-8.
2
[Amplification of proto-oncogenes C-myc, C-N-ras, C-Ki-ras, C-erbB2 in ovarian carcinoma].
Zhonghua Fu Chan Ke Za Zhi. 1995 Jul;30(7):406-9.
3
Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.卵巢癌中C-erbB-2(HER-2/neu)原癌基因的扩增
Chin Med J (Engl). 1994 Aug;107(8):589-93.
4
Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.人乳腺癌中c-myc、c-erbB-2和c-Ha-ras原癌基因的遗传改变及临床关联
Cancer Res. 1989 Dec 1;49(23):6675-9.
5
Oncogene patterns in breast and ovarian carcinomas.
Eur J Surg Oncol. 1993 Dec;19(6):593-9.
6
Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients.
Anticancer Res. 1995 Jul-Aug;15(4):1501-10.
7
HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.HER-2/neu原癌基因在Ⅰ期和Ⅲ期卵巢乳头状浆液性癌中的扩增
Exp Mol Pathol. 1999 Jun;66(2):163-9. doi: 10.1006/exmp.1999.2255.
8
[The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas].
Zhonghua Yi Xue Za Zhi. 1994 Nov;74(11):683-5, 710.
9
[Amplification of C-erB2 gene in ovarian cancer].[卵巢癌中C-erB2基因的扩增]
Zhonghua Fu Chan Ke Za Zhi. 1994 Jul;29(7):401-3, 444.
10
[A study of amplifications of myc gene (c-myc and N-myc) in human ovarian cancer].[人卵巢癌中myc基因(c-myc和N-myc)扩增的研究]
Nihon Sanka Fujinka Gakkai Zasshi. 1990 Mar;42(3):259-63.

引用本文的文献

1
c-MYC-Driven Polyamine Metabolism in Ovarian Cancer: From Pathogenesis to Early Detection and Therapy.c-MYC驱动的卵巢癌多胺代谢:从发病机制到早期检测与治疗
Cancers (Basel). 2023 Jan 19;15(3):623. doi: 10.3390/cancers15030623.
2
c-MYC and Epithelial Ovarian Cancer.c-MYC与上皮性卵巢癌
Front Oncol. 2021 Feb 26;11:601512. doi: 10.3389/fonc.2021.601512. eCollection 2021.
3
Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.
c-MYC基因扩增及8号染色体多倍体在次优切除的晚期上皮性卵巢癌中的预后相关性:一项妇科肿瘤学组研究
Gynecol Oncol. 2009 Sep;114(3):472-9. doi: 10.1016/j.ygyno.2009.05.012. Epub 2009 Jun 12.
4
Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.联合阵列比较基因组杂交和组织芯片分析表明,位于11q13.5-q14的PAK1是卵巢癌中的一个关键致癌基因靶点。
Am J Pathol. 2003 Sep;163(3):985-92. doi: 10.1016/S0002-9440(10)63458-X.